Literature DB >> 28742013

First Canadian experience with donation after cardiac death simultaneous pancreas and kidney transplants.

Patrick T Anderson1, Shahid Aquil1, Kelly McLean1, Vivian C McAlister1, Alp Sener1, Patrick P Luke1.   

Abstract

BACKGROUND: Compared with neurologic determination of death (NDD) donor organs, donation after cardiac death (DCD) donor organs have traditionally been considered of inferior quality owing to warm ischemia experienced during procurement. We present, to our knowledge, the first analysis of simultaneous pancreas and kidney (SPK) transplants using DCD donor organs in Canada.
METHODS: We carried out a retrospective cohort study of SPK transplants from 13 DCD and 68 NDD donors performed between October 2008 and July 2016. In all patients immunosuppression was induced with thymoglobulin and continued with tacrolimus, mycophenolate mofetil and prednisone maintenance therapy.
RESULTS: Donor and recipient characteristics of DCD and NDD groups were similar with respect to age, sex, body mass index, kidney and pancreas cold ischemia times, and donor terminal creatinine. Mean DCD graft warm ischemia time was 0.5 (range 0.4-0.7) hours. Median follow-up was 2.2 (range 0.1-6.7) years and 2.7 (range 0.3-6.3) years for the DCD and NDD groups, respectively. The DCD and NDD groups were similar with regards to recipient percent panel reactive antibody and presence of human leukocyte antigen antibodies. The groups also received similar total doses of thymoglobulin. In total 38% of patients in the DCD group experienced renal delayed graft function (DGF) compared with 10% in the NDD group (p = 0.027). There were 7 cases of pancreas graft thrombosis requiring relaparotomy in the NDD group compared with none in the DCD group. No patients from either group required insulin at any time after transplant. Although the estimated glomerular filtration rate (eGFR) was lower in the DCD than the NDD group on postoperative days 7 and 14 (p = 0.025), no difference was noted on day 30 or through 4 years after transplant. No differences were seen between the groups with respect to amylase, lipase, or glycosated hemoglobin (HbA1c) up to 4 years after transplant, or in kidney, pancreas, or patient survival at any time after transplant.
CONCLUSION: Our results show that, apart from a higher renal DGF rate, SPK transplants with DCD donor organs have comparable outcomes to standard transplants with NDD donor organs.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28742013      PMCID: PMC5608581          DOI: 10.1503/cjs.011315

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  16 in total

1.  Organ donation and transplantation in the UK-the last decade: a report from the UK national transplant registry.

Authors:  Rachel J Johnson; Lisa L Bradbury; Kate Martin; James Neuberger
Journal:  Transplantation       Date:  2014-01-15       Impact factor: 4.939

Review 2.  Delayed graft function in the kidney transplant.

Authors:  A Siedlecki; W Irish; D C Brennan
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

3.  Simultaneous pancreas-kidney transplantation from donation after cardiac death: successful long-term outcomes.

Authors:  Luis A Fernandez; Antonio Di Carlo; Jon S Odorico; Glen E Leverson; Brian D Shames; Yolanda T Becker; L Thomas Chin; John D Pirsch; Stuart J Knechtle; David P Foley; Hans W Sollinger; Anthony M D'Alessandro
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

4.  Declining numbers of pancreas transplantations but significant improvements in outcome.

Authors:  A C Gruessner; R W G Gruessner
Journal:  Transplant Proc       Date:  2014 Jul-Aug       Impact factor: 1.066

5.  Outcomes of pancreas transplantation in the United States using cardiac-death donors.

Authors:  P R Salvalaggio; D B Davies; L A Fernandez; D B Kaufman
Journal:  Am J Transplant       Date:  2006-05       Impact factor: 8.086

6.  Kidney and pancreas transplantation in the United States, 1998-2007: access for patients with diabetes and end-stage renal disease.

Authors:  K P McCullough; D S Keith; K H Meyer; P G Stock; K L Brayman; A B Leichtman
Journal:  Am J Transplant       Date:  2009-04       Impact factor: 8.086

7.  One thousand simultaneous pancreas-kidney transplants at a single center with 22-year follow-up.

Authors:  Hans W Sollinger; Jon S Odorico; Yolanda T Becker; Anthony M D'Alessandro; John D Pirsch
Journal:  Ann Surg       Date:  2009-10       Impact factor: 12.969

8.  Simultaneous pancreas and kidney transplantation from organ donation after cardiac death.

Authors:  Nancy Suh; Brendan Ryan; Richard Allen; Philip O'Connell; Henry Pleass
Journal:  ANZ J Surg       Date:  2009-04       Impact factor: 1.872

9.  Kidney and pancreas transplantation in the United States, 1996-2005.

Authors:  K A Andreoni; K L Brayman; M K Guidinger; C M Sommers; R S Sung
Journal:  Am J Transplant       Date:  2007       Impact factor: 8.086

10.  A Reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation.

Authors:  Randall S Sung; Min Zhang; Douglas E Schaubel; Xu Shu; John C Magee
Journal:  Transplantation       Date:  2015-09       Impact factor: 4.939

View more
  3 in total

1.  The history of renal transplantation in Canada: A urologic perspective.

Authors:  Max Alexander Levine; Joseph L Chin; Andrew Rasmussen; Alp Sener; Patrick P Luke
Journal:  Can Urol Assoc J       Date:  2020-12       Impact factor: 1.862

Review 2.  Pancreas Transplantation from Donors after Circulatory Death: an Irrational Reluctance?

Authors:  M Leemkuil; H G D Leuvenink; R A Pol
Journal:  Curr Diab Rep       Date:  2019-11-18       Impact factor: 4.810

3.  The efficacy of HBOC-201 in ex situ gradual rewarming kidney perfusion in a rat model.

Authors:  Paria Mahboub; Mohamed Aburawi; Negin Karimian; Florence Lin; Murat Karabacak; Fermin Fontan; Shannon N Tessier; James Markmann; Heidi Yeh; Korkut Uygun
Journal:  Artif Organs       Date:  2019-08-01       Impact factor: 3.094

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.